Rafi Malu, Mathew John M, Nair Lekha M, Thomas Kainickal Cessal, George Preethi Sara, Thomas Shaji, Kumar R Rejnish
Department of Radiation Oncology, Regional Cancer Centre, Thiruvananthapuram, India.
Department of Radiation Oncology, Government Medical College, Thiruvananthapuram, India.
Cancer Treat Res Commun. 2025 Aug 6:100968. doi: 10.1016/j.ctarc.2025.100968.
External Auditory Canal (EAC) Squamous cell cancers are rare head and neck malignancies accounting for 0.2% of cancers of this region which has limited literature to guide management.We report a retrospective study patients with SCC of EAC treated at a Tertiary Cancer Centre in India.
We have retrospectively reviewed the case files of patients with biopsy proven SCC of EAC treated at our Institute between 1st Jan 2005 to 31st Dec 2019. All patients were staged using TNM criteria and re-staged as per the Modified Pittsburg criteria and the NEW stage grouping proposed by George et al. The primary objectives of our analysis were estimation of Overall Survival (OS) and Disease Free Survival (DFS) and the secondary objectives included patterns of failure and evaluating factors affecting survival.
Thirty-nine patients were included with a mean age of 55.5 years and 56% being female. More than 50% had stage I /II disease and 46% had stage III/ IV disease as per TNM criteria;10 patients underwent primary surgery.5 had adjuvant radiotherapy (RT) 24 underwent radical radiotherapy. The Median follow up of the group was 85 months with an OS of 70.7% (SE=7.9) and DFS of 47.4% (SE=8.2) at 5 years. Facial nerve palsy and the new staging grouping were found to be predictors of OS in multivariate analysis.
There is an unmet need for developing the optimal staging system that can best predict the outcomes for SCC of EAC. Early Stage disease can have good outcomes with either radiotherapy or surgery.
外耳道(EAC)鳞状细胞癌是罕见的头颈部恶性肿瘤,占该区域癌症的0.2%,相关文献有限,难以指导治疗。我们报告了一项在印度一家三级癌症中心接受治疗的EAC鳞状细胞癌患者的回顾性研究。
我们回顾性分析了2005年1月1日至2019年12月31日在我院接受活检证实为EAC鳞状细胞癌患者的病历。所有患者均按照TNM标准进行分期,并根据改良匹兹堡标准和乔治等人提出的新分期分组进行重新分期。我们分析的主要目的是评估总生存期(OS)和无病生存期(DFS),次要目的包括失败模式和评估影响生存的因素。
纳入39例患者,平均年龄55.5岁,女性占56%。根据TNM标准,超过50%的患者为I/II期疾病,46%的患者为III/IV期疾病;10例患者接受了原发手术,5例接受了辅助放疗(RT),24例接受了根治性放疗。该组患者的中位随访时间为85个月,5年时的OS为70.7%(SE=7.9),DFS为47.4%(SE=8.2)。多因素分析发现面神经麻痹和新的分期分组是OS的预测因素。
开发能够最佳预测EAC鳞状细胞癌预后的最佳分期系统的需求尚未得到满足。早期疾病无论是放疗还是手术都能取得良好的效果。